Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INXN-4001 in LVAD Heart Failure
NCT03409627Phase 1Completed
- Sponsor
- Triple-Gene LLC
- Start
- Apr 2018
- Primary completion
- Mar 2020
- Modality
- Gene Editing, Gene Silencing, Plasmid DNA
- Countries
- 1
01
Overview
Phase 1, open-label trial of INXN-4001 in heart failure (HF) (2 arms), sponsored by Triple-Gene LLC. Primary endpoint: Incidence of all study intervention-related adverse events at 6 months. Started Apr 2018; status: completed.
02
Drugs
INXN-4001
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT03409627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03409627.